Efficacy and Safety of BP02 (Trastuzumab Biosimilar) in HER2-Positive Metastatic Breast Cancer: A Multicenter Phase III Study
Clinical Drug Investigation · 2024-07 · 44 (7) · 513-525
DOI: 10.1007/s40261-024-01374-y ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Clinical Drug Investigation, online erschienen am 27.06.2024. Verfasst von M V T Krishna Mohan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Basavatarakam Indo American Cancer Hospital and Research Institute, Hyderabad, India. Hauptthemen laut MEDLINE: Breast Neoplasms, Biosimilar Pharmaceuticals, Erb-b2 Receptor Tyrosine Kinases, Trastuzumab. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
BACKGROUND AND OBJECTIVE: Trastuzumab targets human epidermal growth factor receptor 2 (HER2) receptors and is indicated for treating HER2-positive metastatic breast cancer. BP02, a recombinant IgG1 kappa humanized monoclonal antibody, is being developed as a trastuzumab biosimilar. The objective of this study was to evaluate the equivalence of BP02 with reference trastuzumab (RT: Herceptin®-EU) in patients with HER2-positive metastatic breast cancer. METHODS: This double-blinded, 1:1 randomized, parallel-group, active-controlled, phase III equivalence trial recruited women aged 18-75 years with histologically/cytologically confirmed HER2- positive, locally recurrent or metastatic breast cancer with systemic metastasis, from 59 sites in India. Patients were randomly allocated 1:1 stratified by estrogen receptor/progesterone receptor status to receive BP02/RT (8-mg/kg loading dose on day 1-cycle 1, 6 mg/kg on day 1-cycles 2-8, of each 3-week cycle) combined with docetaxel (75 mg/m2 on day 1-cycles 1-8) [induction phase]. Participants with complete or partial response, or stable disease at the end of the induction phase continued the study drug until disease progression/treatment discontinuation [maintenance phase]. The primary efficacy endpoint was the objective response rate per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. RESULTS: Between 23 September, 2020 and 16 September, 2022, 690 patients were recruited (n = 345 each to BP02/RT). At the end of the induction phase (intent-to-treat population), a similar proportion of patients achieved an objective response rate with BP02 (n = 231 [67.0%], 95% confidence interval [CI] 62.0, 71.9) and RT (n = 238 [69.0%], 95% CI 64.1, 73.9). The 95% CI of risk difference (-2.03, 95% CI -9.15, 5.09) and 90% CI of risk ratio (0.97, 90% CI 0.89, 1.06) were within equivalence margins of ± 13% and (0.80, 1.25), respectively. Treatment-emergent adverse events leading to treatment withdrawal were reported in 2.9% and 3.2% patients with BP02 and RT, respectively. CONCLUSIONS: BP02 showed an equivalent efficacy and similar safety profile to RT at the end of 24 weeks. CLINICAL TRIAL REGISTRATION: CTRI Number: CTRI/2020/04/024456.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Basavatarakam Indo American Cancer Hospital and Research Institute, Hyderabad, India.
- CuraTeQ Biologics Private Limited, Unit XVII, SyNo. 77&78, Indrakaran (v), Sangareddy Dist, Hyderabad, 502329, India. Arpitkumar.Prajapati@curateqbio.com.
- Narayana Multispecialty Hospital, Ahmedabad, India.
- Radiotherapy Department, NRS Medical College and Hospital, Kolkata, India.
- MNJ Institute of Oncology and Regional Cancer Centre, Hyderabad, India.
- HCG Manavata Cancer Centre, Nashik, India.
Zitieren
APA
Mohan, M. V. T. K., Prajapati, A., Kothari, R., Mandal, S., Rao Srikanth, R., Nagarkar, R., Khane, S., Santa, A., & Dadke, D. (2024). Efficacy and Safety of BP02 (Trastuzumab Biosimilar) in HER2-Positive Metastatic Breast Cancer: A Multicenter Phase III Study. Clinical Drug Investigation, 44(7), 513-525. https://doi.org/10.1007/s40261-024-01374-y
Vancouver
Mohan MVTK, Prajapati A, Kothari R, Mandal S, Rao Srikanth R, Nagarkar R, et al. Efficacy and Safety of BP02 (Trastuzumab Biosimilar) in HER2-Positive Metastatic Breast Cancer: A Multicenter Phase III Study. Clinical Drug Investigation. 2024;44(7):513-525. doi:10.1007/s40261-024-01374-y
BibTeX
@article{Mohan2024,
author = {Mohan, M V T Krishna and Prajapati, Arpitkumar and Kothari, Rushabh and Mandal, Srikrishna and Rao Srikanth, Ranganatha and Nagarkar, Rajnish and Khane, Shriram and Santa, Ayyagari and Dadke, Disha},
title = {Efficacy and Safety of BP02 (Trastuzumab Biosimilar) in HER2-Positive Metastatic Breast Cancer: A Multicenter Phase III Study},
journal = {Clinical Drug Investigation},
year = {2024},
volume = {44},
number = {7},
pages = {513--525},
doi = {10.1007/s40261-024-01374-y}
}
EUVIMED